141 related articles for article (PubMed ID: 36463006)
21. The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma.
Steiner T; Kirchner H; Siebels M; Doehn C; Heynemann H; Varga Z; Rohde D; Schubert J; Jocham D; Stief C; Fornara P; Hofmann R; Loening S; Roigas J
J Cancer Res Clin Oncol; 2010 Jun; 136(6):905-10. PubMed ID: 20012752
[TBL] [Abstract][Full Text] [Related]
22. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
Mosca A; De Giorgi U; Procopio G; Basso U; Cartenì G; Bersanelli M; Naglieri E; Galli L; Caffo O; Fornarini G; Boccardo F; Porta C
Jpn J Clin Oncol; 2021 Mar; 51(3):484-491. PubMed ID: 33212499
[TBL] [Abstract][Full Text] [Related]
23. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
24. Long-term patient survival after the surgical treatment of bone and soft-tissue metastases from renal cell carcinoma.
Higuchi T; Yamamoto N; Hayashi K; Takeuchi A; Abe K; Taniguchi Y; Kato S; Murakami H; Tsuchiya H
Bone Joint J; 2018 Sep; 100-B(9):1241-1248. PubMed ID: 30168767
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of surgical treatment for bone metastatic lesion in renal cell carcinoma].
Mikami K; Nakagawa S; Sugimoto K; Nomoto T; Urano S; Nakamura T; Watanabe H
Hinyokika Kiyo; 1995 Apr; 41(4):241-4. PubMed ID: 7785552
[TBL] [Abstract][Full Text] [Related]
26. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.
McKay RR; Kroeger N; Xie W; Lee JL; Knox JJ; Bjarnason GA; MacKenzie MJ; Wood L; Srinivas S; Vaishampayan UN; Rha SY; Pal SK; Donskov F; Tantravahi SK; Rini BI; Heng DY; Choueiri TK
Eur Urol; 2014 Mar; 65(3):577-84. PubMed ID: 23962746
[TBL] [Abstract][Full Text] [Related]
27. Factors affecting survival in 267 consecutive patients undergoing surgery for spinal metastasis from renal cell carcinoma.
Tatsui CE; Suki D; Rao G; Kim SS; Salaskar A; Hatiboglu MA; Gokaslan ZL; McCutcheon IE; Rhines LD
J Neurosurg Spine; 2014 Jan; 20(1):108-16. PubMed ID: 24206037
[TBL] [Abstract][Full Text] [Related]
28. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
Psutka SP; Feldman AS; McDougal WS; McGovern FJ; Mueller P; Gervais DA
Eur Urol; 2013 Mar; 63(3):486-92. PubMed ID: 22959191
[TBL] [Abstract][Full Text] [Related]
29. Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib.
Lu X; Gu W; Zhang H; Zhu Y; Shi G; Ye D
Oncotarget; 2016 May; 7(18):26879-87. PubMed ID: 27058898
[TBL] [Abstract][Full Text] [Related]
30. Radiotherapy for Brain Metastases From Renal Cell Carcinoma in the Targeted Therapy Era: The University of Rochester Experience.
Bates JE; Youn P; Peterson CR; Usuki KY; Walter KA; Okunieff P; Milano MT
Am J Clin Oncol; 2017 Oct; 40(5):439-443. PubMed ID: 25730604
[TBL] [Abstract][Full Text] [Related]
31. Case report: Complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors.
Asano Y; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Higuchi T; Taniguchi Y; Morinaga S; Horimoto T; Nakai M; Kadono Y; Nojima T; Tsuchiya H
Front Immunol; 2022; 13():980456. PubMed ID: 36238308
[TBL] [Abstract][Full Text] [Related]
32. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC
Eur Urol Oncol; 2020 Aug; 3(4):530-539. PubMed ID: 32037304
[TBL] [Abstract][Full Text] [Related]
33. Survival benefit with resection of brain metastases from renal cell carcinoma in the setting of molecular targeted therapy and/or immune therapy.
Huntoon K; Damante M; Wang J; Olencki T; Elder JB
Curr Probl Cancer; 2022 Apr; 46(2):100805. PubMed ID: 34836657
[TBL] [Abstract][Full Text] [Related]
34. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.
Keizman D; Ish-Shalom M; Pili R; Hammers H; Eisenberger MA; Sinibaldi V; Boursi B; Maimon N; Gottfried M; Hayat H; Peer A; Kovel S; Sella A; Berger R; Carducci MA
Eur J Cancer; 2012 May; 48(7):1031-7. PubMed ID: 22409947
[TBL] [Abstract][Full Text] [Related]
35. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
Colomba E; Le Teuff G; Eisen T; Stewart GD; Fife K; Larkin J; Biondo A; Pickering L; Srinivasan A; Boyle H; Derosa L; Sternberg CN; Recine F; Ralph C; Saldana C; Barthélémy P; Bernhard JC; Gurney H; Verhoest G; Vauleon E; Bigot P; Berger J; Pfister C; Gravis G; Rodier JM; Culine S; Caty A; Rolland F; Priou F; Escudier B; Albiges L
Eur J Cancer; 2017 Jul; 80():55-62. PubMed ID: 28549248
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcome of patients with pancreatic metastases from renal cell cancer.
Yuasa T; Inoshita N; Saiura A; Yamamoto S; Urakami S; Masuda H; Fujii Y; Fukui I; Ishikawa Y; Yonese J
BMC Cancer; 2015 Feb; 15():46. PubMed ID: 25872621
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
[TBL] [Abstract][Full Text] [Related]
38. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?
Amini A; Altoos B; Bourlon MT; Bedrick E; Bhatia S; Kessler ER; Flaig TW; Fisher CM; Kavanagh BD; Lam ET; Karam SD
Pract Radiat Oncol; 2015; 5(6):e589-e596. PubMed ID: 26142027
[TBL] [Abstract][Full Text] [Related]
39. [Surgical treatment of metastases in renal cell carcinoma].
Langer W; Hofmockel G; Theiss M; Frohmüller H
Urologe A; 1997 Nov; 36(6):548-51. PubMed ID: 9487591
[TBL] [Abstract][Full Text] [Related]
40. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
